Speakers and Faculty


The 2019 NYC Neuromodulation Conference and Neuromodulation: The Science bring together leaders across neuromodulation, pain management, healthcare, and wearables. This unparalleled collection of thought leaders supports an engaging program spanning three days (October 4-6, 2019) with an additional one day of Preconference Workshops (October 3, 2019). See all speakers >>

Ana Maiques MBA

Ana Maiques MBA

Ana Maiques is the CEO of Neuroelectrics, a company aiming to change the way we interact with the brain, developing innovative technologies to monitor and stimulate the brain to help many patients in need. She was nominated by IESE as one of the most influential entrepreneurs under 40 in Spain (2010) and received the EU Prize for Women Innovators from the European Commission EC in 2014 and one of the Most Inspiring Fifty Women in Europe. Neuroelectrics recently received the Best Start-up in Health 2015 bye Wired UK magazine in an amazing event in London. She now lives in Boston where Neuroelectrics was awarded as one of the 2016 Best Entrepreneurial Companies in USA by Entrepreneur Magazine. Neuroelectrics is conducting a FDA IDE clinical trial at Boston Children Hospitals aiming to develop a new therapy for drug resistant epileptic patients using non invasive brain stimulation.Ana Maiques is the CEO of Neuroelectrics, a company aiming to change the way we interact with the brain, developing innovative technologies to monitor and stimulate the brain to help many patients in need. She was nominated by IESE as one of the most influential entrepreneurs under 40 in Spain (2010) and received the EU Prize for Women Innovators from the European Commission EC in 2014 and one of the Most Inspiring Fifty Women in Europe. Neuroelectrics recently received the Best Start-up in Health 2015 bye Wired UK magazine in an amazing event in London. She now lives in Boston where Neuroelectrics was awarded as one of the 2016 Best Entrepreneurial Companies in USA by Entrepreneur Magazine. Neuroelectrics is conducting a FDA IDE clinical trial at Boston Children Hospitals aiming to develop a new therapy for drug resistant epileptic patients using non invasive brain stimulation.